Logo image of BTMD

BIOTE CORP -A (BTMD) Stock Overview

USA - NASDAQ:BTMD - US0906831039 - Common Stock

2.89 USD
-0.05 (-1.7%)
Last: 10/24/2025, 8:11:48 PM
2.89 USD
0 (0%)
After Hours: 10/24/2025, 8:11:48 PM

BTMD Key Statistics, Chart & Performance

Key Statistics
Market Cap142.88M
Revenue(TTM)199.07M
Net Income(TTM)31.31M
Shares49.44M
Float28.97M
52 Week High6.98
52 Week Low2.71
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)0.98
PE2.95
Fwd PE8.42
Earnings (Next)11-05 2025-11-05/amc
IPO2021-03-02
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


BTMD short term performance overview.The bars show the price performance of BTMD in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30

BTMD long term performance overview.The bars show the price performance of BTMD in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40

The current stock price of BTMD is 2.89 USD. In the past month the price decreased by -3.34%. In the past year, price decreased by -43.66%.

BIOTE CORP -A / BTMD Daily stock chart

BTMD Latest News, Press Relases and Analysis

BTMD Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 51.11 781.26B
JNJ JOHNSON & JOHNSON 18.34 458.55B
AZN ASTRAZENECA PLC-SPONS ADR 18.76 258.24B
NVS NOVARTIS AG-SPONSORED ADR 14.73 252.36B
NVO NOVO-NORDISK A/S-SPONS ADR 13.65 235.32B
MRK MERCK & CO. INC. 11.36 218.53B
PFE PFIZER INC 7.3 140.77B
SNY SANOFI-ADR 14.34 125.85B
BMY BRISTOL-MYERS SQUIBB CO 6.51 89.21B
GSK GSK PLC-SPON ADR 9.67 86.97B
ZTS ZOETIS INC 23.46 64.68B
TAK TAKEDA PHARMACEUTIC-SP ADR 50.04 44.25B

About BTMD

Company Profile

BTMD logo image biote Corp. is a woman-led company, which engages in providing bio identical hormone pellet therapy. The company is headquartered in Irving, Texas and currently employs 217 full-time employees. The company went IPO on 2021-03-02. The firm provides the necessary components to enable Biote-certified practitioners to establish, build and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, end-to-end practice building platform that provides Biote-certified practitioners with the components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. The company also sells a complementary Biote-branded line of dietary supplements. The Biote Method’s proprietary clinical decision support (CDS) software assists physicians in establishing individualized dosing for patients.

Company Info

BIOTE CORP -A

1875 W. Walnut Hill Ln #100, Floor 5

Irving TEXAS US

Employees: 217

BTMD Company Website

BTMD Investor Relations

Phone: 19724869346

BIOTE CORP -A / BTMD FAQ

Can you describe the business of BIOTE CORP -A?

biote Corp. is a woman-led company, which engages in providing bio identical hormone pellet therapy. The company is headquartered in Irving, Texas and currently employs 217 full-time employees. The company went IPO on 2021-03-02. The firm provides the necessary components to enable Biote-certified practitioners to establish, build and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, end-to-end practice building platform that provides Biote-certified practitioners with the components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. The company also sells a complementary Biote-branded line of dietary supplements. The Biote Method’s proprietary clinical decision support (CDS) software assists physicians in establishing individualized dosing for patients.


What is the stock price of BIOTE CORP -A today?

The current stock price of BTMD is 2.89 USD. The price decreased by -1.7% in the last trading session.


What is the dividend status of BIOTE CORP -A?

BTMD does not pay a dividend.


What is the ChartMill rating of BIOTE CORP -A stock?

BTMD has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 5 out of 10.


On which exchange is BTMD stock listed?

BTMD stock is listed on the Nasdaq exchange.


How is the valuation of BIOTE CORP -A (BTMD) based on its PE ratio?

The PE ratio for BIOTE CORP -A (BTMD) is 2.95. This is based on the reported non-GAAP earnings per share of 0.98 and the current share price of 2.89 USD.


Can you provide the short interest for BTMD stock?

The outstanding short interest for BIOTE CORP -A (BTMD) is 3.22% of its float.


BTMD Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

BTMD Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to BTMD. BTMD has only an average score on both its financial health and profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BTMD Financial Highlights

Over the last trailing twelve months BTMD reported a non-GAAP Earnings per Share(EPS) of 0.98. The EPS increased by 366.67% compared to the year before.


Industry RankSector Rank
PM (TTM) 15.73%
ROA 29.87%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%220%
Sales Q2Q%-0.62%
EPS 1Y (TTM)366.67%
Revenue 1Y (TTM)-14.94%

BTMD Forecast & Estimates

12 analysts have analysed BTMD and the average price target is 5.51 USD. This implies a price increase of 90.7% is expected in the next year compared to the current price of 2.89.

For the next year, analysts expect an EPS growth of 166.59% and a revenue growth -2.93% for BTMD


Analysts
Analysts81.67
Price Target5.51 (90.66%)
EPS Next Y166.59%
Revenue Next Year-2.93%

BTMD Ownership

Ownership
Inst Owners64.32%
Ins Owners9.75%
Short Float %3.22%
Short Ratio6.91